PUBLISHER: The Business Research Company | PRODUCT CODE: 1712411
PUBLISHER: The Business Research Company | PRODUCT CODE: 1712411
Diuretic drugs are medications that facilitate an increase in urine flow by reducing the concentration of sodium and chloride in the body. They aid in the removal of excess salt (sodium) and water, often referred to as 'water tablets.' Examples of diuretic drugs include Diuril, Microzide, and Indapamide.
The main categories of diuretics encompass osmotic diuretics, carbonic anhydrase inhibitors, loop diuretics, thiazides and thiazide-like diuretics, and aldosterone antagonists. Osmotic diuretics prevent the reabsorption of water and sodium and are typically administered intravenously as pharmacologically inactive compounds. They are employed in the treatment of conditions like hypertension, glaucoma, heart failure, and kidney stones. These diuretics are distributed through various channels, including hospital pharmacies, independent pharmacies, retail pharmacies, drug stores, and online pharmacies.
The diuretics market research report is one of a series of new reports from The Business Research Company that provides diuretics market statistics, including diuretics industry global market size, regional shares, competitors with a diuretics market share, detailed diuretics market segments, market trends and opportunities, and any further data you may need to thrive in the diuretics industry. This diuretics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The diuretics market size has grown steadily in recent years. It will grow from $0.74 billion in 2024 to $0.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to prevalence of chronic diseases, aging population, clinical guidelines, pharmaceutical innovation, increase in obesity.
The diuretics market size is expected to see steady growth in the next few years. It will grow to $0.89 billion in 2029 at a compound annual growth rate (CAGR) of 3.5%. The growth in the forecast period can be attributed to rising incidence of hypertension and heart failure, emerging markets, government initiatives, focus on preventive healthcare. Major trends in the forecast period include personalized medicine, innovative drug development, telehealth and remote monitoring, digital health solutions.
The diuretics market is on an upward trajectory due to the increasing prevalence of renal and kidney disorders. When the kidneys fail to function properly, there is a heightened demand for diuretic drugs, commonly known as water pills, to ensure the proper flow of urine. Lifestyle changes, including the consumption of unhealthy, mineral-rich foods, are contributing to the rise in kidney disorders. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that approximately 14% of U.S. adults, equating to around 35.5 million individuals, are affected by chronic kidney disease. This rising prevalence of renal and kidney disorders is significantly driving the growth of the diuretics market.
The diuretics market is anticipated to be fueled by the increasing incidence of cardiac disorders. Cardiac disorders encompass a range of medical conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and arrhythmias. Diuretics play a pivotal role in managing cardiovascular diseases by reducing excess bodily fluids, lowering blood pressure, and easing the workload on the heart. This, in turn, improves the overall management of conditions such as hypertension and congestive heart failure. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government agency, revealed that in 2023, over 1.86 million people (3%) in England had received a GP diagnosis of coronary heart disease (CHD). This rise in the incidence of cardiac disorders is contributing to the growth of the diuretics market.
Major companies in the diuretics market are focusing on developing innovative products, such as prescription medications, to enhance treatment efficacy and minimize side effects for patients with conditions like hypertension and heart failure. Prescription medications are those that require a doctor's prescription, ensuring their appropriate use under professional supervision for specific medical conditions. For example, in January 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched a generic version of the diuretic Bumetanide Injection for treating fluid retention and swelling associated with conditions like congestive heart failure. This product is available in two formulations: 1 mg/4 mL single-dose vials and 2.5 mg/10 mL multi-dose vials, both containing a concentration of 0.25 mg/mL. The injection is used to effectively treat edema caused by conditions such as congestive heart failure, liver disease, and kidney disease, promoting increased urine production to alleviate symptoms such as swelling and difficulty breathing.
Major companies are introducing innovative products like FUROSCIX to expand their global presence and gain a competitive edge. FUROSCIX is a subcutaneous furosemide injection that offers an alternative method for administering diuretic medication to manage fluid overload in patients with heart failure. For instance, scPharmaceuticals Inc. announced FDA approval for FUROSCIX in October 2022, specifically for treating congestion caused by fluid overload in adults with New York Heart Association Class II/III chronic heart failure. FUROSCIX provides at-home IV-equivalent diuresis through the FUROSCIX Infusor and is the first and only FDA-approved subcutaneous loop diuretic.
In November 2022, Novo Integrated Sciences Inc., a healthcare company, and Clinical Consultants International LLC, a hospital consulting firm, entered into a consulting agreement with Sarfez Pharmaceuticals Inc. for an FDA-approved edema treatment targeting patients with heart failure and renal disease. Utilizing their extensive network of hospitals, physicians, and independent pharmacies, CCI and the Novo team will collaborate with Sarfez on the marketing and distribution of the commercially available SOAANZ treatment. Sarfez Pharmaceuticals Inc. is a pharmaceutical research and development company.
Major companies operating in the diuretics market include Merck & Co. Inc., Meda Manufacturing GmbH, Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, Aton Pharma Inc., Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi-aventis U.S. LLC, Centaur Pharmaceuticals Pvt Ltd., Validus Pharmaceuticals LLC, Actavis Generics, Paddock Laboratories LLC, Perrigo Pharmaceutical Company, H. Lundbeck Inc., Oak Pharmaceuticals Inc., Akron Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Aurobindo Pharma Limited, IPCA Laboratories Limited, Jubilant Cadista Pharmaceuticals Limited, Mylan N.V., Princeton Laboratories Inc., Sciegen Pharma Limited, Unichem Laboratories Limited, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Cipla Ltd., F Hoffmann-La Roche Ltd., Fresenius Kabi AG, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Amneal Pharmaceuticals LLC, Apotex Inc.
North America was the largest region in the diuretics market in 2024. The Middle East is expected to be the fastest-growing region in the diuretics market during the forecast period. The regions covered in the diuretics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the diuretics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada
The diuretics market consists of sales of diuril, microzide, and indapamide. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diuretics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diuretics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for diuretics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diuretics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.